SecBot SecBot
SECBOTREPLAY Home › Report › CCCC

CCCC · C4 Therapeutics entered a research collaboration and license agreement…

C4 Therapeutics, Inc. · 8-K filed Apr 9, 2026 at 07:07 ET

At the news

BULLISHIMPACT 7/10

8-K filed Apr 9, 2026 at 07:07 ET

C4 Therapeutics entered a research collaboration and license agreement with Roche to develop degrader-antibody conjugates (DACs) for two undisclosed oncology targets, with an option for a third. The deal includes a $20 million upfront payment and over $1 billion in potential milestone payments plus royalties. This partnership leverages C4T's TORPEDO platform and Roche's ADC expertise.

  • C4 Therapeutics and Roche entered a collaboration agreement for degrader-antibody conjugates (DACs)
  • Roche will develop, manufacture, and commercialize DACs directed to two initial undisclosed oncology targets
  • C4T receives $20 million upfront payment
  • C4T is eligible to receive over $1.0 billion in aggregate milestone payments

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access